65,437 trials
Solid Tumors · Head and Neck Cancer · Lung Cancer
Primary: Phase 1 : Number of Treatment-Emergent Adverse Events (TEAE) — 6; 3; 4; 4 Participants
Chronic Obstructive Pulmonary Disease
Primary: Change in Sputum Bacteria Biomass — -0.24; -0.14 log10 molecules/uL/mL
Atrial Fibrillation · End Stage Renal Disease
Primary: Number of Participants Experiencing ISTH (International Society on Thrombosis and Haemostasis) Major or Clinically Relevant Non-major Bleeding — 21; 16 Participants…
Antithrombotic
Primary: The Number of Adverse Events (AEs), Serious AEs (SAEs), AEs Leading to Discontinuation and Death — 4; 4; 3; 2 Participants
Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose — 0; 0; 0; 0 Participants
PreDiabetes · Circadian Dysregulation
Primary: Change in Glucose Levels (Area-under-the-curve) Measured by Performance on Oral Glucose Tolerance Test (OGTT) — -11.3 mg*h/dL — p=.046
Systemic Lupus Erythematosus
Primary: Serum Concentration of Belimumab Following Intravenous Administration — 0.0; 26567.4; 63403.2; 64474.6 Nanograms per milliliter
Sleep-disordered Breathing · Snoring
Primary: Pleural Pressure (Pes) — 9.3; 4.4 mmHg
Keloid
Primary: Change in Keloid Surface Area — 0.455; -0.039 cm2
Peripheral Arterial Disease
Primary: Number of Patients With Lesion Success — 22 Participants
Communication
Primary: Family Member-reported Quality of End of Life Communication (QOC) Received From Study Surgeon — 6.6; 4.5 score on a scale — p=0.006
Endovascular Procedures
Primary: Cohen's Kappa Coefficient (κ) — 0.84 proportion of agreement
Nasal Polyposis
Primary: Change in Total Polys Score (TPS) — -0.5; -0.3; -0.2 score on a scale
Antifungal Agents
Primary: Maximum Plasma Concentration (Cmax) for Griseofulvin — 2229; 2877; 1927 Nanograms per milliliter
Leukemia · Lymphoma
Primary: Bone Loss Reduction: Mean Percent Changes in BMD for Each Treatment Arm at the 6 Months — -2.4; -3.5; -7.6; -11 Percent of change